P

Pfizer

Makes cancer drugs, vaccines and other medicines

Group Leader - Immune Reset

Full-TimePosted on 10/20/2026Deadline 10/31/26
$162.9k - $271.5k/yr+ 20% bonus target + Share-based long-term incentive program
Senior
PhD, MD
Cambridge, MA, USA
HybridMust live within commuting distance and work on-site an average of 2.5 days per week.
Biology & BiotechTranslational Research & Bench Biology
No H1B Sponsorship

About the job

Requirements
  • A PhD, MD, or MD/PhD equivalent degree is required.
  • At least 5 years of related work experience in academia, biotechnology, or pharmaceutical research is required.
  • A proven track record of developing, leading, and influencing early-stage discovery programs is required.
  • Deep immunology expertise, particularly understanding how cell-depletion approaches may improve treatment outcomes for autoimmune disease, is required.
  • Extensive experience in immunology drug discovery in a high-caliber research environment such as biotechnology or pharmaceuticals is required.
  • The candidate must create an inclusive environment that values diverse ideas, viewpoints, and backgrounds.
  • The candidate must demonstrate commitment to talent development, inclusion, and creating a high-performing team culture grounded in scientific excellence, rigor, integrity, and company values.
  • Experience leading programs using antibody, multispecific, antibody-drug conjugate, T-cell engager, or other innovative immune-cell-depleting modalities is essential.
  • The candidate must collaborate effectively across discovery biology, translational sciences, pharmacology, safety, systems immunology, and platform groups, and establish productive external collaborations with academic investigators and key opinion leaders.
  • Experience with preclinical assay development, mammalian genetics, systems biology, and the biological architecture of autoimmune, inflammatory, and fibrotic disease is preferred.
  • A strong publication record and experience managing and developing bench-based scientists are preferred.
  • Experience with common artificial intelligence tools, including generative tools such as ChatGPT or Microsoft Copilot, is preferred.
  • The candidate must be authorized to work in the United States by any employer and have permanent U.S. work authorization; U.S. work visa sponsorship is unavailable.
Responsibilities
  • Lead the Immune Reset Group within the Inflammation and Immunology Research Unit Discovery team, refining strategy and biology focus to advance the portfolio.
  • Provide biology expertise to internal teams developing next-generation cell-depletion therapies for rheumatological, dermatological, gastroenterological, neurological, and respiratory diseases.
  • Serve as a core member of the Discovery Leadership Team, advancing immune-system-reset biology and selective cell-depletion approaches into the drug discovery pipeline.
  • Lead from the bench by designing and executing key experiments to inform go/no-go decisions at critical project stages.
  • Help develop and execute a drug development pipeline aligned with key scientific objectives in discovery immunology research.
  • Provide expert advice and share knowledge with direct reports, peers, and senior leadership.
  • Establish and manage external collaborations with leading research laboratories worldwide, including attending and presenting at conferences and submitting publications.
  • Manage, grow, and develop scientists and lead multiple complex research programs in parallel.
Desired Qualifications
  • Demonstrated ability to work with teams, establish and cultivate networks, and maintain productive collaborations.
  • Experience coaching and mentoring junior scientists and motivating a team.
  • Willingness and ability to lead inclusively, listen to, and consider all points of view.
  • Ability to work, influence, lead, and deliver results in cross-functional teams.
  • Strong written, presentation, and interpersonal communication skills, including effectiveness in highly collaborative environments.
  • Several first- or senior-author publications in high-impact journals.
  • Ability to build trusted, productive relationships across multidisciplinary teams and functions, including biology, translational sciences, pharmacology, safety, systems immunology, platform technologies, clinical partners, and external collaborators.
  • Learning agility to assimilate complex scientific, technical, and strategic information, identify essential issues, and adapt direction to emerging data, portfolio priorities, or business needs.
  • Scientific curiosity and a continuous-improvement mindset, including challenging assumptions, raising scientific standards, and advancing innovative approaches.
  • Ability to lead with accountability, sound judgment, and data-driven decision-making in a fast-paced discovery research environment.
  • Ability to influence without authority, align diverse stakeholders, and clearly communicate scientific rationale, risks, and recommendations to project teams and senior leaders.

About the company

Pfizer discovers, makes, and sells prescription medicines and vaccines for patients, doctors, and governments worldwide, with large businesses in vaccines, cancer, heart disease, and rare diseases. In 2020, its COVID-19 shot, developed with German partner BioNTech, became the first COVID-19 vaccine authorized in the United States. Its scientists find drug candidates and run clinical trials to prove they are safe and effective, and Pfizer then manufactures approved products in its own plants, earning most of its money from patented drugs before cheaper generic copies arrive. Pfizer was founded in 1849 as a chemicals business in Brooklyn and is based in New York City.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Newer drugs carry the business: launched and acquired products grew 18% operationally in Pfizer's August 2026 quarterly report.
  • The outlook improved: in August 2026, Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion.
  • Vaccine scientists get room to grow: Pfizer's $470 million Pearl River, New York research expansion is designed for 370 workers.

What critics are saying

  • Expect more site cuts: in November 2025, Pfizer moved to shrink Swiss staff from about 300 to roughly 70.
  • Generics will erase sales: Pfizer expects patent losses to cut $17 billion to $18 billion of yearly revenue through 2028.
  • Pfizer is chasing obesity leaders: Metsera's monthly shot showed 12.3% weight loss at 28 weeks in February 2026 data.

What makes Pfizer unique

  • Pfizer bought its way into cancer: its Seagen buyout added antibody-drug conjugates, which carry chemotherapy straight to tumors.
  • Pfizer is betting on monthly obesity shots: Metsera's berobenatide is dosed once a month, unlike weekly Wegovy and Zepbound.
  • Pfizer leans on one partnered heart drug: blood thinner Eliquis, sold with Bristol Myers Squibb, brings about 14% of revenue.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-3%
Yahoo Finance
Oct 21st, 2026
Pfizer announces layoffs at Rocky Mount and Sanford sites, but gives no numbers

Pfizer has announced layoffs at its Rocky Mount and Sanford facilities in North Carolina, as part of a push to improve efficiency. It told employees of the cuts on Tuesday but did not say how many jobs will go, when, or in which departments. Rocky Mount makes sterile injectables, while Sanford focuses on vaccines and advanced biologics, including gene therapies. "Headcount reductions are a part of this initiative," Pfizer said, adding that it will give affected staff support services. "If indeed this happens, it's going to affect those families," said David Farris, president and chief executive officer of the Rocky Mount Area Chamber of Commerce. The impact on local economies, he said, depends on the number laid off. As of Wednesday afternoon, no Worker Adjustment and Retraining Notification (WARN) notice had been filed with the state.

Yahoo Finance
Oct 19th, 2026
Five low-beta dividend stocks: Pfizer yields 5.83%, Coca-Cola raises payout since 1999

Five defensive dividend stocks offer income with less volatility than the broader market, according to a 24/7 Wall St. analysis. All five have a beta well below 1, meaning they have historically moved less than the market. Pfizer leads with a forward yield of 5.83% at $29.49 a share. AT&T yields 4.77% at $23.27, and its $1.11 dividend uses about 42% of 2026 free cash flow guidance of $18B+. Debt of $144B is its main risk. Dominion Energy yields 4.24%, while Coca-Cola and Colgate-Palmolive each yield 2.27%. Coca-Cola has raised its dividend every year since 1999, and Colgate's next ex-dividend date is October 20, 2026.

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.

Yahoo Finance
Oct 14th, 2026
Pfizer's 6% dividend pays investors to wait as oncology pipeline drives growth beyond COVID-19

Pfizer offers a dividend yield of just over 6% while it builds growth beyond its COVID-19 products. The drugmaker declared a quarterly dividend of $0.43 in June 2026, its 351st consecutive quarterly payment. In the second quarter, revenue from launched and acquired products rose 18% year over year. Pfizer raised the midpoint of its full-year guidance, helped by stronger non-COVID sales from drugs such as Eliquis, Padcev, and Vyndaqel. Oncology is the next focus. Pfizer is investing in antibody-drug conjugates and bispecific antibodies, and it entered a global collaboration with Innovent Biologics covering 12 early-stage cancer programs. Not every experimental drug will succeed, but a broader pipeline improves the odds. If new medicines work, the share price could rise on top of the dividend income.

Yahoo Finance
Oct 13th, 2026
Six high-yield dividend stocks fail the payout test, from Ford to Whirlpool's 9.37% mirage

High dividend yields can hide weak payouts, and a four-step test helps separate real income from traps. It checks earnings with one-offs stripped out, full-year free cash flow against dividends, management's explanation, and whether debt funds the gap. Ford yields 4.99% and shows a trailing EPS of -$1.88, caused by $4.2B in one-time charges. Its debt-to-equity of 4.66 leaves the $0.60 dividend exposed to a downturn. Pfizer yields 6.03%, but its free cash flow yield is 5.60%. Clorox's roughly $405M of free cash flow fell short of about $601M in dividends. Whirlpool fails every step. It cut its quarterly dividend from $1.75 to $0.90 in 2025, paid no common dividend in the second quarter of 2026, and its shares are down 59.48% since the end of 2025. 3M and Dow pass, with payouts now covered by cash.